GT Biopharma Ownership 2024 | Who Owns GT Biopharma Now?
Institutional Ownership
0.00%
Insider Ownership
6.67%
Retail Ownership
93.33%
Institutional Holders
1.00
GT Biopharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RETIREMENT GROUP, LLC | 0.00% | - | 1 | -43 | -97.73% | 4 | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -16 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,073 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -300,719 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -32,347 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -79,976 | -100.00% | - | Mar 31, 2024 |
| VANGUARD GROUP INC | - | - | - | -1,087,993 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | - | - | - | -22,867 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -8,078 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -596,240 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -114,695 | -100.00% | - | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -337,315 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -65,953 | -100.00% | - | Mar 31, 2024 |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -304,041 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -95,239 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,320 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -57,807 | -100.00% | - | Mar 31, 2024 |
| WELCH GROUP, LLC | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -37,180 | -100.00% | - | Mar 31, 2024 |
GT Biopharma's largest institutional shareholder is RETIREMENT GROUP, LLC, holding 0.00% of the company's total share outstanding, currently valued at $4.00. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RETIREMENT GROUP, LLC | 0.00% | - | 1 | -43 | -97.73% | 4 | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -16 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,073 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -300,719 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -32,347 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -79,976 | -100.00% | - | Mar 31, 2024 |
| VANGUARD GROUP INC | - | - | - | -1,087,993 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | - | - | - | -22,867 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -8,078 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -596,240 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -114,695 | -100.00% | - | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -337,315 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -65,953 | -100.00% | - | Mar 31, 2024 |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -304,041 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -95,239 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,320 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -57,807 | -100.00% | - | Mar 31, 2024 |
| WELCH GROUP, LLC | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -37,180 | -100.00% | - | Mar 31, 2024 |
The largest GT Biopharma shareholder by % of total assets is RETIREMENT GROUP, LLC. The company owns 1.00 shares of GT Biopharma (GTBP), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -16 | -100.00% | - | Mar 31, 2024 |
| RETIREMENT GROUP, LLC | 0.00% | - | 1 | -43 | -97.73% | 4 | Mar 31, 2024 |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | - | - | - | -1,017 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,073 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -8,078 | -100.00% | - | Mar 31, 2024 |
| WELCH GROUP, LLC | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -14,605 | -100.00% | - | Mar 31, 2024 |
| JANE STREET GROUP, LLC | - | - | - | -19,405 | -100.00% | - | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -19,775 | -100.00% | - | Mar 31, 2024 |
| MOSS ADAMS WEALTH ADVISORS LLC | - | - | - | -20,000 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | - | - | - | -22,867 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -32,347 | -100.00% | - | Mar 31, 2024 |
| HRT FINANCIAL LP | - | - | - | -33,785 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,320 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -37,180 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -57,807 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -65,953 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -79,976 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, GT Biopharma's largest institutional buyer is QUBE RESEARCH & TECHNOLOGIES LTD. The company purchased -2.00 stocks of GTBP, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | - | - | - | -1,087,993 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -596,240 | -100.00% | - | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -337,315 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -304,041 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -300,719 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -114,695 | -100.00% | - | Mar 31, 2024 |
| ATRIA WEALTH SOLUTIONS, INC. | - | - | - | -98,720 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -95,239 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -79,976 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -65,953 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -57,807 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -37,180 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,320 | -100.00% | - | Mar 31, 2024 |
| HRT FINANCIAL LP | - | - | - | -33,785 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -32,347 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | - | - | - | -22,867 | -100.00% | - | Mar 31, 2024 |
| MOSS ADAMS WEALTH ADVISORS LLC | - | - | - | -20,000 | -100.00% | - | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -19,775 | -100.00% | - | Mar 31, 2024 |
| JANE STREET GROUP, LLC | - | - | - | -19,405 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -14,605 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, GT Biopharma's biggest institutional seller is VANGUARD GROUP INC. The company sold -1.09M shares of GTBP, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | - | - | - | -1,087,993 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -596,240 | -100.00% | - | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -337,315 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -304,041 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -300,719 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -114,695 | -100.00% | - | Mar 31, 2024 |
| ATRIA WEALTH SOLUTIONS, INC. | - | - | - | -98,720 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -95,239 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -79,976 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -65,953 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -57,807 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -37,180 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,320 | -100.00% | - | Mar 31, 2024 |
| HRT FINANCIAL LP | - | - | - | -33,785 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -32,347 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | - | - | - | -22,867 | -100.00% | - | Mar 31, 2024 |
| MOSS ADAMS WEALTH ADVISORS LLC | - | - | - | -20,000 | -100.00% | - | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -19,775 | -100.00% | - | Mar 31, 2024 |
| JANE STREET GROUP, LLC | - | - | - | -19,405 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -14,605 | -100.00% | - | Mar 31, 2024 |
| WELCH GROUP, LLC | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -8,078 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,073 | -100.00% | - | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | - | - | - | -1,017 | -100.00% | - | Mar 31, 2024 |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -16 | -100.00% | - | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
GT Biopharma's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -1.09M shares, valued at -, as of undefined.
GT Biopharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.03% | 16,775 | - | - | Dec 31, 2023 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 2,456 | - | - | Dec 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 34,934 | - | - | Dec 31, 2023 |
| Fidelity Commonwealth Trust II | 0.00% | 32,905 | - | - | Aug 31, 2023 |
| VANGUARD INDEX FUNDS | 0.00% | 1,396,560 | 315,885 | 29.23% | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 701 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 324,587 | - | - | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 17,977 | - | - | Dec 31, 2023 |
| AdvisorShares Trust | 0.00% | 2,426 | - | - | Dec 29, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 1,870 | - | - | Dec 31, 2023 |
| SCHWAB CAPITAL TRUST | 0.00% | 25,869 | - | - | Feb 29, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,400 | - | - | Dec 31, 2023 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 7,958 | - | - | Dec 31, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 6,559 | - | - | Dec 31, 2023 |
| TIAA-CREF LIFE FUNDS | 0.00% | 453 | - | - | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,081 | - | - | Feb 29, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 135,548 | - | - | Feb 29, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 4,200 | - | - | Dec 31, 2023 |
| ProFunds | 0.00% | 380 | - | - | Jan 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 171 | - | - | Dec 31, 2023 |
| Invesco Exchange-Traded Self-Indexed Fund Trust | 0.00% | 7,201 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 900 | - | - | Dec 29, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 59,063 | - | - | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 93 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 6,577 | - | - | Feb 29, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 18,707 | - | - | Jan 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 105 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,259 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 2,317 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 17,029 | - | - | Dec 31, 2023 |
| RYDEX VARIABLE TRUST | 0.00% | 17 | - | - | Dec 31, 2023 |
| Goldman Sachs ETF Trust | 0.00% | 1,060 | - | - | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 9,466 | - | - | Dec 29, 2023 |
| PROSHARES TRUST | 0.00% | 2,557 | - | - | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 972 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 19,100 | - | - | Dec 31, 2023 |
| VANGUARD WELLINGTON FUND | 0.00% | 2,547 | - | - | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 11,471 | - | - | Dec 31, 2023 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 9,992 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 5,278 | - | - | Dec 31, 2023 |
| iSHARES TRUST | 0.00% | 64,979 | - | - | Feb 29, 2024 |
| PACIFIC SELECT FUND | 0.00% | 7,617 | - | - | Dec 31, 2023 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,653 | - | - | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 500 | - | - | Jan 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 2,844 | - | - | Dec 31, 2023 |
| PRINCIPAL FUNDS, INC. | 0.00% | 3,252 | - | - | Feb 29, 2024 |
| Bridge Builder Trust | 0.00% | 1,966 | - | - | Dec 31, 2023 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 5,100 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 1,529 | - | - | Feb 29, 2024 |
| John Hancock Funds II | 0.00% | 3,103 | - | - | Feb 29, 2024 |
GT Biopharma's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 16.77K shares, compromising 0.03% of its total assets.
GT Biopharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 1 | -96.43% |
| 31 Dec, 23 | 28 | - |
| 30 Sep, 23 | 28 | -9.68% |
| 30 Jun, 23 | 31 | -6.06% |
| 31 Mar, 23 | 33 | 6.45% |
| 31 Dec, 22 | 31 | 3.33% |
| 30 Sep, 22 | 30 | -28.57% |
| 30 Jun, 22 | 42 | -23.64% |
| 31 Mar, 22 | 55 | 7.84% |
| 31 Dec, 21 | 51 | -3.77% |
| 30 Sep, 21 | 53 | 12.77% |
| 30 Jun, 21 | 47 | 176.47% |
| 31 Mar, 21 | 17 | - |
| 30 Jun, 20 | 1 | - |
As of 31 Mar 24, 1 institutions are holding GT Biopharma's shares, representing a decrease of -96.43% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 1 | -100.00% |
| 31 Dec, 23 | 3,393,512 | -0.46% |
| 30 Sep, 23 | 3,409,025 | 3.59% |
| 30 Jun, 23 | 3,290,804 | -33.64% |
| 31 Mar, 23 | 4,959,315 | -21.68% |
| 31 Dec, 22 | 6,332,203 | 156.51% |
| 30 Sep, 22 | 2,468,639 | -19.09% |
| 30 Jun, 22 | 3,051,112 | -31.45% |
| 31 Mar, 22 | 4,450,713 | -17.32% |
| 31 Dec, 21 | 5,383,333 | 14.61% |
| 30 Sep, 21 | 4,697,170 | 4.60% |
| 30 Jun, 21 | 4,490,786 | 698.39% |
| 31 Mar, 21 | 562,481 | - |
| 30 Jun, 20 | 750 | - |
GT Biopharma (GTBP) has 1.00 shares outstanding as of 31 Mar 24, down -100.00% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 0.00% | - |
| 31 Dec, 23 | 8.27% | 11.49% |
| 30 Sep, 23 | 8.49% | 11.97% |
| 30 Jun, 23 | 8.42% | 5.23% |
| 31 Mar, 23 | 12.69% | 3.21% |
| 31 Dec, 22 | 19.87% | 32.11% |
| 30 Sep, 22 | 7.87% | 8.25% |
| 30 Jun, 22 | 9.77% | 5.20% |
| 31 Mar, 22 | 13.70% | 4.66% |
| 31 Dec, 21 | 17.15% | 7.66% |
| 30 Sep, 21 | 14.97% | 8.34% |
| 30 Jun, 21 | 13.40% | 475.74% |
| 31 Mar, 21 | 1.68% | - |
| 30 Jun, 20 | 0.00% | - |
As of 31 Mar 24, GT Biopharma is held by 0.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | - | -100.00% |
| 31 Dec, 23 | 13 | 30.00% |
| 30 Sep, 23 | 10 | 11.11% |
| 30 Jun, 23 | 9 | -18.18% |
| 31 Mar, 23 | 11 | -35.29% |
| 31 Dec, 22 | 17 | 88.89% |
| 30 Sep, 22 | 9 | -30.77% |
| 30 Jun, 22 | 13 | -7.14% |
| 31 Mar, 22 | 14 | -54.84% |
| 31 Dec, 21 | 31 | 19.23% |
| 30 Sep, 21 | 26 | -36.59% |
| 30 Jun, 21 | 41 | 141.18% |
| 31 Mar, 21 | 17 | - |
| 30 Jun, 20 | 1 | - |
- institutional shareholders have increased their position in GTBP stock as of 31 Mar 24 compared to 13 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 1 | -75.00% |
| 31 Dec, 23 | 4 | -42.86% |
| 30 Sep, 23 | 7 | -22.22% |
| 30 Jun, 23 | 9 | 12.50% |
| 31 Mar, 23 | 8 | 60.00% |
| 31 Dec, 22 | 5 | -61.54% |
| 30 Sep, 22 | 13 | -31.58% |
| 30 Jun, 22 | 19 | -26.92% |
| 31 Mar, 22 | 26 | 420.00% |
| 31 Dec, 21 | 5 | -70.59% |
| 30 Sep, 21 | 17 | 325.00% |
| 30 Jun, 21 | 4 | - |
| 31 Mar, 21 | - | - |
| 30 Jun, 20 | - | - |
1 institutional shareholders have reduced their position in GTBP stock as of 31 Mar 24 compared to 4 in the previous quarter (a -75.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 1 | -96.43% | 1 | -100.00% | 0.00% | - | - | -100.00% | 1 | -75.00% |
| 31 Dec, 23 | 28 | - | 3,393,512 | -0.46% | 8.27% | 11.49% | 13 | 30.00% | 4 | -42.86% |
| 30 Sep, 23 | 28 | -9.68% | 3,409,025 | 3.59% | 8.49% | 11.97% | 10 | 11.11% | 7 | -22.22% |
| 30 Jun, 23 | 31 | -6.06% | 3,290,804 | -33.64% | 8.42% | 5.23% | 9 | -18.18% | 9 | 12.50% |
| 31 Mar, 23 | 33 | 6.45% | 4,959,315 | -21.68% | 12.69% | 3.21% | 11 | -35.29% | 8 | 60.00% |
| 31 Dec, 22 | 31 | 3.33% | 6,332,203 | 156.51% | 19.87% | 32.11% | 17 | 88.89% | 5 | -61.54% |
| 30 Sep, 22 | 30 | -28.57% | 2,468,639 | -19.09% | 7.87% | 8.25% | 9 | -30.77% | 13 | -31.58% |
| 30 Jun, 22 | 42 | -23.64% | 3,051,112 | -31.45% | 9.77% | 5.20% | 13 | -7.14% | 19 | -26.92% |
| 31 Mar, 22 | 55 | 7.84% | 4,450,713 | -17.32% | 13.70% | 4.66% | 14 | -54.84% | 26 | 420.00% |
| 31 Dec, 21 | 51 | -3.77% | 5,383,333 | 14.61% | 17.15% | 7.66% | 31 | 19.23% | 5 | -70.59% |
| 30 Sep, 21 | 53 | 12.77% | 4,697,170 | 4.60% | 14.97% | 8.34% | 26 | -36.59% | 17 | 325.00% |
| 30 Jun, 21 | 47 | 176.47% | 4,490,786 | 698.39% | 13.40% | 475.74% | 41 | 141.18% | 4 | - |
| 31 Mar, 21 | 17 | - | 562,481 | - | 1.68% | - | 17 | - | - | - |
| 30 Jun, 20 | 1 | - | 750 | - | 0.00% | - | 1 | - | - | - |
GT Biopharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of GT Biopharma's stock was made by Ohri Manu on Aug 15 2023, selling 200,000 shares at $0.29 per share (valued at $57.40K). The last insider buy of GTBP was made by Breen Michael Martin on Apr 11 2023, buying 50,000 shares at $0.50 per share (worth $25.00K).
GT Biopharma Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2023 | 2 | - | - |
| Q1 2023 | 4 | - | - |
| Q3 2022 | 6 | 1 | 600.00% |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | 1 | - | - |
| Q1 2021 | 9 | 1 | 900.00% |
| Q4 2020 | 3 | 16 | 18.75% |
| Q2 2020 | - | 3 | - |
| Q3 2019 | 2 | - | - |
| Q1 2019 | - | 2 | - |
| Q4 2017 | - | 3 | - |
| Q3 2017 | 2 | 3 | 66.67% |
| Q2 2016 | 1 | 1 | 100.00% |
| Q1 2016 | - | 5 | - |
| Q1 2012 | 1 | - | - |
| Q3 2011 | 1 | - | - |
| Q2 2011 | 1 | 2 | 50.00% |
| Q4 2010 | 2 | 7 | 28.57% |
| Q3 2010 | - | 10 | - |
2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by GT Biopharma's insiders, as of Q2 2023.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2023 | 2 | - | - |
| Q1 2023 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q1 2021 | - | - | - |
| Q4 2020 | 3 | 16 | 18.75% |
| Q2 2020 | - | 2 | - |
| Q3 2019 | - | - | - |
| Q1 2019 | - | 2 | - |
| Q4 2017 | - | - | - |
| Q3 2017 | - | - | - |
| Q2 2016 | - | 1 | - |
| Q1 2016 | - | - | - |
| Q1 2012 | - | - | - |
| Q3 2011 | - | - | - |
| Q2 2011 | 1 | - | - |
| Q4 2010 | - | 4 | - |
| Q3 2010 | - | 10 | - |
As of Q2 2023, Insider owners conducted 2 open market buy trades and 0 open market sell trades of GT Biopharma's stocks.
GT Biopharma Peer Ownership
| Ticker | Company |
|---|---|
| CVKD | Cadrenal Therapeutics, Inc. Common Stock |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| SRZN | Surrozen, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| VRAX | Virax Biolabs Group Limited |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| SABS | SAB Biotherapeutics, Inc. |
| ONCR | Oncorus, Inc. |
| VRPX | Virpax Pharmaceuticals, Inc. |
| REVB | Revelation Biosciences, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| LABP | Landos Biopharma, Inc. |
| PULM | Pulmatrix, Inc. |
| HILS | Tharimmune, Inc. |
| ALLR | Allarity Therapeutics, Inc. |
| AKTX | Akari Therapeutics, Plc |
| TARA | Protara Therapeutics, Inc. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| VCNX | Vaccinex, Inc. |
GTBP Ownership FAQ
Who Owns GT Biopharma?
GT Biopharma is owned by institutional shareholders (0.00%), insiders (6.67%), and public (93.33%). The largest institutional shareholder of GT Biopharma is RETIREMENT GROUP, LLC (0.00% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).
Who are the major institutional shareholders of GT Biopharma?
GT Biopharma's major institutional shareholders are RETIREMENT GROUP, LLC, JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, and NORTHERN TRUST CORP. The top five shareholders own together 0.00% of the company's share outstanding.
How many GT Biopharma shareholders are there?
As of Mar 2024, there are 1 institutional shareholders of GT Biopharma.
What percentage of GT Biopharma is owned by RETIREMENT GROUP, LLC?
RETIREMENT GROUP, LLC owns 1 shares of GT Biopharma, representing 0.00% of the company's total shares outstanding, valued at $4 (as of Mar 2024).
What percentage of GT Biopharma is owned by JPMORGAN CHASE & CO?
As of Mar 2024, JPMORGAN CHASE & CO holds 0 shares of GT Biopharma (GTBP), compromising 0% of the company, valued at $0.
What percentage of GT Biopharma is owned by BANK OF AMERICA CORP /DE/?
BANK OF AMERICA CORP /DE/ is the third largest holder of GT Biopharma. The company owns 0 of the company's shares outstanding (worth $0).